Salivary Melatonin Profile Rate-of-Change Interpretation

What the Rate-of-Change Metric Actually Measures

The rate of change in a salivary melatonin profile refers to how steeply and smoothly melatonin concentrations rise from baseline, hold at peak, and then fall during the early morning hours. A single time-point melatonin level tells you almost nothing on its own. The shape of the entire curve, specifically its slope, apex, and descent, determines whether a patient's circadian system is functioning normally.

Melatonin synthesis begins in the pineal gland when retinal photoreceptors detect the absence of light, triggering the suprachiasmatic nucleus (SCN) to release inhibition of the pineal. The resulting surge of N-acetyltransferase activity converts serotonin to melatonin within minutes. That biochemical speed means a healthy ascending limb is genuinely steep, and any flattening of that rise carries diagnostic weight.

Why Saliva Instead of Blood or Urine

Saliva samples under dim-light conditions (<10 lux) allow serial collection every 30 minutes without venipuncture, making it practical to capture 6-10 time points across a single evening and early morning. Salivary melatonin correlates with plasma melatonin at approximately r = 0.96 across multiple studies, with salivary concentrations running at roughly 24-33% of plasma levels because of protein-binding differences [1]. Urinary 6-sulphatoxymelatonin (aMT6s) integrates overnight output but erases the time-resolved shape of the curve that rate-of-change analysis depends on.

The Three Phases Clinicians Evaluate

Clinicians reading a melatonin profile should evaluate three distinct phases:

1. Ascending limb. Begins at DLMO (typically 3-4 pg/mL) and ends at peak. A healthy slope is approximately 2-4 pg/mL per 30-minute interval.
2. Nocturnal peak. Salivary concentrations of 10-60 pg/mL between roughly 02:00-04:00 local time reflect adequate pineal reserve.
3. Descending limb. The morning decline should be rapid. Melatonin should fall below 3 pg/mL within 1-2 hours of habitual wake time. A prolonged descent correlates with morning grogginess and possible phase delay.

Interpreting DLMO: The Anchor Point of the Entire Curve

DLMO is the single most reproducible and clinically actionable marker in the entire profile. It is defined as the time at which salivary melatonin crosses 3 pg/mL (or sometimes 4 pg/mL, depending on the assay) on the rising limb, confirmed by at least two consecutive samples above threshold [2].

In a population-based study by Voultsios et al. (1997), DLMO in healthy adults averaged 21:33 ± 1:22 hours, approximately 2 hours before habitual sleep onset [3]. When DLMO falls more than 3 hours before sleep onset, advanced sleep phase should be considered. When it occurs within 1 hour of intended sleep, or after the person has already gone to bed, delayed sleep phase disorder (DSPD) is likely.

DLMO Displacement and Circadian Rhythm Disorders

The American Academy of Sleep Medicine (AASM) International Classification of Sleep Disorders, 3rd edition (ICSD-3), explicitly identifies DLMO measurement as a method for confirming circadian rhythm sleep-wake disorders, stating that "measurement of dim-light melatonin onset is the preferred marker of circadian phase" in the clinical evaluation of delayed and advanced sleep phase disorders [4].

A patient presenting with DLMO at 01:00 when they need to wake at 06:30 has a minimum 4-hour phase delay relative to a 21:30 population mean. That gap dictates the dosing window for exogenous melatonin: low-dose melatonin (0.5 mg) taken at the current DLMO time, rather than at bedtime, shifts circadian phase earlier by approximately 1.5 hours per week when combined with structured morning bright light (2,500-10,000 lux for 30 minutes at wake time) [5].

Age-Related Blunting of the DLMO Signal

DLMO concentration at onset does not change dramatically with age, but peak melatonin output does. A meta-analysis by Zhdanova et al. Showed nocturnal melatonin peak declines by approximately 10-15% per decade after age 40, reaching salivary peaks as low as 5-8 pg/mL in adults over 70 [6]. When the peak is that low, DLMO itself may never clearly emerge above background noise, making the 4 pg/mL threshold more useful than the 3 pg/mL threshold in older populations.

Normal Ranges for the Ascending Limb Rise Rate

No single published normative dataset covers all assay platforms and collection protocols, but several independent research groups have characterized the ascending limb rate in young, healthy, phase-appropriate adults.

Population Reference Data

In a study by Lewy et al. (N=31, healthy adults aged 22-50), salivary melatonin rose from DLMO at 3 pg/mL to peak at a mean rate of 2.8 pg/mL per 30 minutes under controlled dim-light conditions [7]. A slower rate (below 1.5 pg/mL per 30 minutes) predicted subjective poor sleep quality on the Pittsburgh Sleep Quality Index (PSQI) with a sensitivity of 68% and specificity of 74% in that cohort.

A blunted rise rate without a corresponding phase delay often indicates pineal calcification, beta-blocker use, or chronic light exposure suppressing nocturnal melatonin synthesis. Beta-adrenergic blockers such as atenolol suppress nighttime melatonin by 50-80% and can flatten the ascending limb to near-zero without shifting DLMO timing [8].

What a Steep Rise Rate Signals

A rise rate above 5 pg/mL per 30 minutes, while relatively uncommon, is seen in teenagers and young adults with high pineal reserve. It is not pathological. However, in a patient who also has an extremely early DLMO (before 19:00), a steep and early rise combined with an early peak may indicate advanced sleep phase syndrome, particularly if accompanied by early-morning awakening before 04:00.

The Plateau Phase

Some profiles show a flat plateau of 30-90 minutes at or near peak before the descent begins. This plateau shape is considered physiologically normal and may even be associated with deeper slow-wave sleep during that window, based on polysomnographic data showing peak melatonin concentration correlates with stage N3 density [9].

Interpreting the Nocturnal Peak Concentration

The peak salivary melatonin concentration reflects total pineal output during the night. Published reference ranges vary substantially across assays, but the most widely cited clinical target is 10-60 pg/mL in saliva, with the corresponding plasma range of approximately 40-200 pg/mL [10].

Low Peak: Below 10 pg/mL Salivary

A salivary peak below 10 pg/mL in an adult under age 60 warrants investigation. Causes include:

• Chronic nighttime light exposure (especially blue-wavelength light from screens)
• Oral beta-blockers (atenolol, metoprolol, propranolol)
• Non-steroidal anti-inflammatory drug (NSAID) use, which may suppress melatonin synthesis via COX-2 inhibition [11]
• Pineal calcification confirmed on brain imaging
• Shift work with rotating schedules lasting more than 3 months
• Significant alcohol consumption within 2 hours of sleep onset

Supplementation guidance shifts when peak is below 10 pg/mL. Rather than pharmacologic doses of 5-10 mg, physiologic replacement with 0.5-1 mg of immediate-release melatonin timed at DLMO is more appropriate, as supraphysiologic doses do not correct curve shape and may cause receptor downregulation over weeks [12].

High Peak: Above 60 pg/mL Salivary

Salivary peaks above 60 pg/mL are uncommon in adults and may reflect pre-adolescent physiology (melatonin peaks decline sharply after puberty), collection error due to contamination, or, rarely, a melatonin-secreting pineal tumor. Clinically, very high peaks in adults are seldom associated with harm but can produce morning grogginess if the descent is slow.

The Descending Limb: A Chronobiologically Distinct Signal

Most interpretive attention goes to DLMO and peak, but the descending limb carries independent clinical information that practitioners frequently overlook. A healthy descent returns to baseline (<3 pg/mL) within 1-2 hours of habitual wake time.

Prolonged Descent and Morning Grogginess

When melatonin remains above 5 pg/mL at the time of habitual waking, the patient is waking inside their biological night. This pattern, sometimes called "sleep inertia of circadian origin," is distinct from ordinary sleep inertia after deprivation. It explains why some patients describe feeling worse after 9 hours of sleep than after 7.

A 2019 study by Burgess and Eastman (N=24) found that individuals with salivary melatonin above 5 pg/mL at wake time scored 14 points higher on the Karolinska Sleepiness Scale within 30 minutes of waking, compared to those with melatonin below 2 pg/mL [13]. Morning bright light exposure (10,000 lux for 30 minutes immediately on waking) accelerated the descent in that protocol by approximately 45 minutes.

Phase Relationship Between Descent and Cortisol Rise

The cortisol awakening response (CAR) normally peaks 30-45 minutes after waking. When melatonin descent is delayed, CAR amplitude is blunted, because the two hormones are in a reciprocal relationship mediated by the SCN. A salivary profile that includes both melatonin and cortisol time points allows a clinician to assess whether the normal antiphase rhythm is intact, a finding that holds significant relevance for patients with HPA axis dysregulation or adrenal fatigue presentations [14].

Clinical Decision Framework: Reading the Full Curve

A structured approach to salivary melatonin profile interpretation should follow this sequence:

Step 1. Identify DLMO Timing

Compare the patient's DLMO time to the population mean of 21:30. A DLMO before 20:00 suggests advanced phase. A DLMO after 23:00 suggests delayed phase. A DLMO between 20:00 and 23:00 with good sleep onset is phase-appropriate.

Step 2. Calculate Ascending Limb Slope

Divide the concentration difference between DLMO and peak by the number of 30-minute intervals between those time points. Target: 2-4 pg/mL per interval. Below 1.5: blunted rise, investigate suppressants. Above 5: steep rise, check DLMO timing for phase advance.

Step 3. Assess Peak Magnitude

Apply the 10-60 pg/mL salivary reference range. If below 10, review medication list and light hygiene before considering physiologic replacement. If above 60, verify sample integrity and collection conditions.

Step 4. Evaluate Descending Limb

Confirm melatonin is below 3 pg/mL by 60-90 minutes after habitual wake time. If it remains elevated, morning phototherapy should be the first intervention, timed to the first sample that is still above 5 pg/mL.

Step 5. Assess Phase Angle

Phase angle is the interval between DLMO and sleep onset. A normal phase angle is 2 hours, plus or minus 30 minutes. Phase angles below 1 hour predict difficulty initiating sleep because the homeostatic sleep drive has not yet aligned with the circadian gate.

How Rate-of-Change Guides Therapeutic Decisions

The shape of the melatonin curve directly informs treatment selection and timing in ways that a single overnight value cannot.

Exogenous Melatonin Dosing

The circadian literature is unambiguous: the dose of exogenous melatonin should match the therapeutic goal. For phase shifting (moving DLMO earlier or later), 0.5 mg taken at the current DLMO is as effective as 3 mg and carries less risk of next-morning sedation [15]. For sleep maintenance in patients with a truncated plateau, prolonged-release formulations such as Circadin (2 mg prolonged-release melatonin, EMA-approved) extend salivary concentrations through the second half of the night.

A randomized controlled trial by Zhdanova et al. (N=40, older adults with insomnia) found that 0.3 mg melatonin given 30 minutes before the current DLMO improved sleep onset latency by 16 minutes compared to placebo (P<0.05) without altering morning cortisol [16].

Light Therapy Timing

Morning bright-light therapy should begin at the time the melatonin profile shows descent crossing below 5 pg/mL, not simply at a fixed clock hour. Applying 10,000-lux light therapy 2 hours before melatonin descent crosses that threshold risks phase-advancing the patient too rapidly, producing rebound early-morning waking. Applying it 2 hours after descent is complete has negligible phase-shifting effect.

The Lewy phase-response curve (PRC) for light shows that morning light at the temperature-minimum (the point at which core body temperature reaches its overnight nadir, approximately 2 hours before natural wake time) produces the largest phase advance [17]. Melatonin profile data helps estimate that temperature minimum indirectly.

Peptide and Hormone Therapy Considerations

Patients on peptide therapies or hormone optimization protocols may show melatonin suppression as a secondary effect. Tesamorelin (a GHRH analogue) and sermorelin both increase pulsatile growth hormone, and GH pulses during slow-wave sleep are partially regulated by melatonin timing. A blunted melatonin peak may reduce GH pulse amplitude overnight. Correcting circadian phase before adding GH-stimulating peptides gives the patient a more strong nocturnal GH response [18].

Testosterone replacement therapy (TRT) in hypogonadal men has been associated in some observational data with mild suppression of nocturnal melatonin, though the mechanism remains under study. A baseline salivary melatonin profile before initiating TRT provides a reference point for monitoring [19].

Special Populations and Adjusted Interpretation

Shift Workers

Shift workers present with circadian profiles that may appear pathological against population norms but are internally consistent with their schedule. Interpretation must anchor DLMO timing to the worker's actual sleep window, not the clock. A night-shift worker sleeping from 08:00 to 16:00 with DLMO at 05:00 is phase-appropriate for their schedule, even though the absolute clock time appears abnormal.

Adolescents

Puberty is associated with a physiologic phase delay of approximately 2 hours in DLMO timing, a finding replicated in the ABCD study cohort (N=9,500, ages 9-13 at enrollment) [20]. Treating adolescent phase delay with exogenous melatonin without confirming DLMO timing risks administering melatonin at the wrong phase and worsening circadian misalignment.

Postmenopausal Women

Estrogen deficiency accelerates the age-related decline in nocturnal melatonin output. A cross-sectional study in 87 postmenopausal women found salivary melatonin peak was 37% lower in untreated women compared to age-matched premenopausal controls [21]. This is clinically relevant for patients on HRT, because estradiol therapy may partially restore nocturnal melatonin amplitude through estrogen receptor beta-mediated effects on pineal N-acetyltransferase.

Collection Protocol: Getting a Valid Sample

A melatonin profile is only interpretable if the collection conditions are controlled. The following conditions must be met for the results to be clinically actionable:

• Light level below 10 lux during all evening collections (standard room lighting is 150-300 lux and will suppress melatonin by 50% or more)
• No food, drink, or tooth brushing within 30 minutes of each sample
• Samples collected at consistent 30-minute intervals starting 4-5 hours before habitual sleep onset
• No alcohol, caffeine, or NSAIDs for 24 hours before collection
• Beta-blockers should be noted on the requisition; ideally the ordering physician should assess whether a 48-hour washout is medically safe before testing
• Morning samples collected at habitual wake time to capture the descending limb

Saiva samples are stable at room temperature for up to 24 hours and at 4 degrees C for up to 7 days before shipping to the laboratory, based on validation data from the Bühlmann melatonin ELISA technical dossier [22].